David Mott

David Mott

Presidente presso ARDELYX, INC.

Patrimonio netto: 21 M $ in data 31/05/2026

60 anni
Health Technology
Finance
Consumer Services

Profilo

Mr. David M.
Mott
is an Independent Director at Novavax, Inc., a Chairman at Ardelyx, Inc. and a Chairman at Cydan LLC.
He is on the Board of Directors at Novavax, Inc., Biotechnology Innovation Organization, NEA 14 GP Ltd. and XTuit Pharmaceuticals, Inc. Mr. Mott was previously employed as a Chairman by Imara, Inc., an Independent Director by Clementia Pharmaceuticals, Inc., an Independent Non-Executive Director by Nightstar Therapeutics Plc, a Chairman by Adaptimmune Ltd., a Chairman by Adaptimmune Therapeutics Plc, a Chairman by Mersana Therapeutics, Inc., a Chairman-Supervisory Board by Prosensa Holding NV, a Chairman by Epizyme, Inc., a General Partner by NEA Management Co. LLC, a General Partner by New Enterprise Associates LLC, a Non-Executive Director by Shire Plc, an Executive Vice President by AstraZeneca PLC, a President by MedImmune Ventures, Inc., a Vice Chairman, President & Chief Executive Officer by MedImmune LLC, a President & Chief Executive Officer by MedImmune Ltd., a Vice President-Health Care Investment Banking by Smith Barney Harris Upham & Co., Inc., a Chairman by Complexa, Inc., a Chairman by Conceptis Technologies, Inc., a Chairman by Cydan II, Inc., a VP-Health Care Investment Banking Group by Harris Upham & Co, Inc., a Chairman by Sagimet Biosciences, Inc., a Member-Governing Board by St. Albans School, a Trustee by St. James' School, a Chairman by Vtesse, Inc., and a Chairman by Zyngenia, Inc. He also served on the board at Polyneuron Pharmaceuticals AG, Tiburio Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Tesaro, Inc., Ambit Biosciences Corp., Biohealth Innovation, Inc., Edimer Pharmaceuticals, Inc., Melinta Subsidiary Corp., NightstaRx Ltd., Shire Pharmaceuticals, Inc., Shire Plc /Old/, Zosano Pharma Corp.
and ZP Opco, Inc. He received his undergraduate degree from Dartmouth College.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
31/03/2026 3.302.918 ( 1,34% ) 20 M $ 31/05/2026
23/04/2026 79.770 ( 0,05% ) 875 077 $ 31/05/2026
11/04/2025 0 ( -.--% ) - $ 31/05/2026
06/01/2026 0 ( -.--% ) - $ 31/12/2025

Posizioni attive di David Mott

SocietàPosizioneInizio
ARDELYX, INC. Presidente 01/03/2014
NOVAVAX, INC. Direttore/Membro del Consiglio 16/06/2020
Presidente -
NEA 14 GP Ltd.
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -
Direttore/Membro del Consiglio -

Precedenti posizioni note di David Mott

SocietàPosizioneFine
MERSANA THERAPEUTICS Amministratore Delegato 02/03/2015
ADAPTIMMUNE THERAPEUTICS PLC Presidente 14/11/2025
IMARA Presidente 01/02/2023
░░░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░░░░░
░░░ ░░░░░░░░░░ ░░░ ░░░ ░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di David Mott

Formazione di David Mott

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

58

Relazioni di 1° grado

45

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private45

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Technology Services

Finance

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Retail Trade

Health Technology

Health Technology

Consumer Services

Finance

Health Technology

Finance

Consumer Services

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Consumer Services

NEA 14 GP Ltd.

Health Technology

Health Technology

Distribution Services

Finance

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

  1. Mercati
  2. Insiders
  3. David Mott
- 40%: I migliori strumenti riservati agli abbonati per individuare le opportunità di investimento di domani.
g
:
:
ENTRA ORA